You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 11,213,480


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,213,480
Title:Phenylephrine hydrochloride ready-to-use solution
Abstract:This invention relates to a dilute, ready-to-use solution of phenylephrine hydrochloride having improved stability and utility. In a particular embodiment, the formulation consists of an injectable form of phenylephrine hydrochloride with edetate disodium chelating agent in place of any sodium metabisulfite antioxidants to improve the solution's ability to remain stable and active in a dilute state after prolonged storage. This invention also relates to a form for injection of the solution that includes packaging the solution in a single-use container, as well as a form for containing the ready-to-use solution in a sterile, sealed container. Lastly this invention relates to methods of making the injectable solution for use in a single-use container, as well as for containment in a sterile, sealed container.
Inventor(s):McAnany David E., Parker Michael G., McCue Sarah D.
Assignee:Hikma Pharmaceuticals International Limited
Application Number:US15230352
Patent Claims: 1. A stable , ready-to-use sterile intravenous injection solution of phenylephrine hydrochloride packaged into a vial for injection , wherein the solution consists essentially of:from about 0.05 mg/mL to about 0.15 mg/mL phenylephrine hydrochloride as the only active pharmaceutical ingredient in the solution;from about 3 mg/mL to about 4 mg/mL of sodium chloride;from about 0.1 mg/mL to about 0.3 mg/mL of edetate disodium (EDTA); andwater;wherein the solution has a pH between 3 and 6.5, is stored in a single use vial, and exhibits 0.2% or less of phenylephrine impurities after exposure to a temperature of 40° C. for a period of 6 months; and wherein the solution is free of bisulfites or other antioxidants.2. A stable , ready-to-use sterile intravenous injection solution of phenylephrine hydrochloride packaged into a vial for injection , wherein the solution consists essentially of:from about 0.05 mg/mL to about 0.15 mg/mL phenylephrine hydrochloride as the only active pharmaceutical ingredient in the solution;from about 3 mg/mL to about 4 mg/mL of sodium chloride;from about 0.1 mg/mL to about 0.3 mg/mL of edetate disodium (EDTA);one or more of a preservative, a buffer and/or a pH adjustor; andwater;wherein the solution has a pH between 3 and 6.5, is stored in a single use vial, and exhibits 0.2% or less of phenylephrine impurities after exposure to a temperature of 40° C. for a period of 6 months; andwherein the solution is free of bisulfites or other antioxidants.3. The solution of claim 2 , wherein the preservative is present and is benzyl alcohol.4. The solution of claim 2 , wherein the buffer is present and is a citrate buffering system for assisting in maintaining the pH of the solution.5. The solution of claim 2 , wherein the pH adjuster is present and is hydrochloric acid claim 2 , sodium hydroxide or both.6. The solution of which exhibits about 0.1% or less of phenylephrine impurities after exposure to a temperature of 40° C. for a period of 6 months.7. The solution of which has:phenylephrine hydrochloride in an amount of about 0.1 mg/mL;sodium chloride in an amount of about 3.64 mg/mL; andedetate disodium in an amount of about 0.2 mg;with the solution having a pH of from 5 to 5.3.8. The solution of claim 7 , wherein one or more of the following are present:benzyl alcohol in an amount of about 8 mg/mL,a buffering system for assisting in maintaining the pH of the solution, and/orhydrochloric acid, sodium hydroxide or both for pH adjustment, if necessary.9. A sterile liquid pharmaceutical product that includes a stable claim 7 , ready-to-use sterile intravenous injection solution of phenylephrine hydrochloride packaged into a vial for injection claim 7 , the vial having less than 10% by volume oxygen content in the head space claim 7 , wherein the solution consists essentially of:from about 0.05 mg/mL to about 0.15 mg/mL phenylephrine hydrochloride as the only active pharmaceutical ingredient in the solution;from about 3 mg/mL to about 4 mg/mL of sodium chloride;from about 0.1 mg/mL to about 0.3 mg/mL of edetate disodium (EDTA); andwater;wherein the solution has a pH between 3 and 6.5, is stored in a single use vial, and exhibits 0.2% or less of phenylephrine impurities after exposure to a temperature of 40° C. for a period of 6 months; and wherein the solution is free of bisulfites or other antioxidants.10. The product of claim 9 , wherein the solution is present in the container or vial in an amount of 0.05 to 20 mL and the head space has an oxygen content of less than 5% by volume.11. The product of claim 9 , wherein the solution is present in an amount that allows only a single use of the container or vial.12. A method for making the stable claim 1 , ready-to-use injection solution of phenylephrine hydrochloride according to claim 1 , which comprises admixing from about 0.05 mg/mL to about 0.15 mg/mL phenylephrine hydrochloride; from about 3 mg/mL to about 4 mg/mL of sodium chloride; from about 0.1 mg/mL to about 0.3 mg/mL of edetate disodium; and water for injection q.s. to form the stable claim 1 , ready-to-use injection solution.13. The method of that further comprises filling a container or vial with from about 0.05 to about 20 mL of the solution.14. The method of claim 13 , which further comprises providing the head space of the container or vial with an oxygen content that is below 10%.15. The method of claim 14 , wherein the oxygen content of the headspace of the container or vial is below 5% by volume and is provided by adding nitrogen to the container or vial.16. The method of claim 13 , which further comprises providing an amount of the solution that allows only a single use of the container or vial.17. A sterile liquid pharmaceutical product that includes the solution of packaged into a container for injection.18. The product of claim 1 , wherein the solution is free of bisulfites or other antioxidants.19. The solution of claim 1 , which further consists essentially of one or more of a preservative claim 1 , a buffer and/or a pH adjustor.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.